発表論文

Prevalence of Chlamydia-associated reactive arthritis

Okamoto H,

Scand J Rheumatol　2017 Sep;46(5):415-416

The pivotal role of the angiotensin-II-NF-κB axis in the development of COVID-19 pathophysiology.

Okamoto H, Ichikawa N.

Hypertens Res. 2021 Jan;44(1):126-128.

IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus.

Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata S, Minota S.

Lupus. 2016 Feb 3. pii: 0961203316629556.

Causes of Death in Autopsied Patients with Rheumatoid Arthritis in Japan.

Kitahama M, Okamoto H, Terai C., Koseki Y., Sakurai T., Kamatani N.

Journal of Arthritis 01/2014; 2:115. DOI: 10.4172/2167-7921.1000115

Smoking and the Microbiome in the Pathogenesis of Rheumatoid Arthritis.

Okamoto H.

Rheumatology (Sunnyvale) 2014, 4: 132

Problems in the Management of Rheumatoid Arthritis in Rural Hospitals of Japan.

Okamoto-H.

Rheumatology (Sunnyvale) 2014, S4-009

Pregnancy In Patients With SLE

Baba S, Okamoto H. Yamanaka H,

Autoimmune Dis Ther Approaches 2015, 2:1 doi: 10.14437/ADTAOA-2-113

Environmental Factors Involved In The Pathogenesis Of Systemic Lupus Erythematosus

Okamoto-H.

Autoimmune Dis Ther Approaches 2014, 1:2 doi: 10.14437/ADTAOA-1-110

Pathogenesis of Neuropsychiatric Syndromes of Systemic Lupus Erythematosus.

Yoshio, T. and Okamoto, H.

Open Journal of Rheumatology and Autoimmune Diseases, 2015, 5, 46-56.

Morinda Citrifolia (Noni) in the Treatment of　Psoriasis.

Okamoto-H.

The Open General and Internal Medicine Journal, 2012, 5, 1-2

IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells.

Yoshio T, Okamoto H, Hirohata S, Minota S.

Arthritis Rheum. 2013 Feb;65(2):457-63.

Major depressive disorder in patients with rheumatoid arthritis.

Sato E, Nishimura K, Nakajima A, Okamoto H, Shinozaki M, Inoue E, Taniguchi A, Momohara S, Yamanaka H.

Mod Rheumatol. 2013 Mar;23(2):237-44.

Systemic lupus erythematosus.

Okamoto H, Cervera R, Rodriguez-Reyna TS, Nishimura H, Yoshio T.

Autoimmune Dis. 2012;2012:815753.

Antiribosomal-P protein antibodies are associated with proliferative glomerulonephritis more strongly than with membranous glomerulonephritis in Japanese patients with systemic lupus erythematosus.

Yoshio T, Okamoto H, Onishi S, Minota S.

Mod Rheumatol. 2012 Jun;22(3):488-90.

Treatment of interstitial lung diseases associated with connective tissue diseases.

Kobayashi A, Okamoto H.

Expert Rev Clin Pharmacol. 2012 Mar;5(2):219-27.

Tyrosine kinases in rheumatoid arthritis.

Okamoto H, Kobayashi A.

J Inflamm (Lond). 2011 Aug 24;8:21.

Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Okamoto H, Kobayashi A.

N Engl J Med. 2011 Jan 6;364(1):83-4.

CISH and susceptibility to infectious diseases.

Okamoto H.

N Engl J Med. 2010 ;363:1675-6.

Molecular architecture of the Goodpasture autoantigen.

Okamoto H.

N Engl J Med. 2010 ;363:1770.

Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis.

Okamoto H, Yoshio T, Kaneko H, Yamanaka H.

Arthritis Rheum. 2010 ;62:82-92.

Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.

Nishimoto K, Kochi Y, Ikari K, Yamamoto K, Suzuki A, Shimane K, Nakamura Y, Yano K, Iikuni N, Tsukahara S, Kamatani N, Okamoto H, Kaneko H, Kawaguchi Y, Hara M, Toyama Y, Horiuchi T, Tao K, Yasumoto K, Hamada D, Yasui N, Inoue H, Itakura M, Yamanaka H, Momohara S.

Ann Rheum Dis. 2010 ;69:368-73.

Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Okamoto H, Kobayashi A, Yamanaka H.

J Biomed Biotechnol. 2010;2010:268436.

Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis.

Kitahama M, Okamoto H, Koseki Y, Inoue E, Kaneko H, Taniguchi A, Momohara S, Yamanaka H.

Mod Rheumatol. 2010 ;20:478-85.

A case of isolated gouty tophus in a patient without a previous history of gouty arthritis.

Kobayashi, S. Taniguchi A. Okamoto H. Momohara S. Tomatsu T.

Journal of Clinical Rheumatology. 2009 ;15:373.

Association of a polymorphism in the monocyte chemoattractant protein-1/CCL2 gene and lupus nephritis in systemic lupus erythematosus patients.

Hoshi D, Okamoto H, Kaneko H, Ichikawa N, Terai C, Yamanaka H, Kamatani N.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5):972-3.

Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein.

Momohara S, Okamoto H, Yamanaka H.

Clin Chim Acta. 2008 ;398:155-6.

Promoter activity of A/G at position -168 in the type III promoter of MHCIITA gene.

Okamoto H., Kaneko H., Terai C., Kamatani N.

Rheumatology (Oxford). 2008 ;47:547-8.

Acute-Phase Serum Amyloid A Activates NF-kB in Rheumatoid Synovial Fibroblasts through Binding to RAGE.

Okamoto H., Katagiri Y., Kiire A., Momohara S., Kamatani N.

J Rheumatol. 2008 ;35:752-6.

Lack of association between anti-ribosomal-P antibody and chemokines in neuropsychiatric syndromes of systemic lupus rythematosus.

Okamoto H., Yoshio T., Kamatani N.

The Open Genral and Internal Medicine Journal. 2008; 2,1-2.

Vitamin K and rheumatoid arthritis.

Okamoto H.

IUBMB Life, 2008 15;60(6):355-361.

Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.

Kobayashi S, Ikari K, Kaneko H, Kochi Y, Yamamoto K, Shimane K, Nakamura Y, Toyama Y, Mochizuki T, Tsukahara S, Kawaguchi Y, Terai C, Hara M, Tomatsu T, Yamanaka H, Horiuchi T, Tao K, Yasutomo K, Hamada D, Yasui N, Inoue H, Itakura M, Okamoto H, Kamatani N, Momohara S.

Arthritis Rheum. 2008 Jul;58(7):1940-6.

Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis.

Okamoto H, Kamatani N.

N Engl J Med. 2008 ;358:1516

Molecular targets of rheumatoid arthritis.

Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N.

Inflamm Allergy Drug Targets. 2008 ;7(1):53-66.

Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients with Rheumatoid Arthritis.

Iwamoto T.,Okamoto H., Toyama Y., Momohara S.

FEBS J. 2008 ;275:4448-55.

Molecular aspects of rheumatoid arthritis: role of environmental factors.

Kobayashi S., Momohara S., Kamatani S., Okamoto H.

FEBS J. 2008 ;275:4456-62.

Molecular aspects of rheumatoid arthritis: role of transcription factors.

Okamoto H., Cujec T.P., Yamanaka H., Kamatani N.

FEBS J. 2008 ;275:4463-70.

Molecular aspects of rheumatoid arthritis: chemokines, environmental factors and transcription factors.

Okamoto H.

FEBS J. 2008 ;275:4447.

MHC2TA is associated with rheumatoid arthritis in Japanese patients.

Iikuni N, Ikari K, Momohara S, Tomatsu T, Hara M, Yamanaka H, Okamoto H, Kamatani N.

Ann Rheum Dis. 2007 Feb;66(2):274-5.

The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis.

Mochizuki T, Momohara S, Ikari K, Okamoto H, Kobayashi S, Tsukahara S, Iwamoto T, Kawamura K, Saito S, Tomatsu T.

Mod Rheumatol. 2007;17(1):24-7.

The Occurrence of Japanese Cedar Pollinosis with Rheumatoid Arthritis.

Koizumi K, Okamoto H, Kamitsuji S, Sato E, Suzuki K, Yamanaka H, HaraM, Tomatsu T, Kamatani N.

Clin Exp Rheumatol. 2007 ;25:505-6.

Spontaneous multiple insufficiency fractures following pelvic abscess and sepsis in a rheumatoid arthritis patient treated with high-load corticosteroid therapy: a case report.

Mochizuki　T., Momohara S., Ikari K., Kawamura K., Tsukahara S., Iwamoto T., Kobayashi S., Okamoto H., Tomatsu T.

Clin Rheumatol. 2007 ;26:1925-8.

Protective effect of A at position -168 in the type III promoter of MHCIITA gene in Systemic Lupus Erythematosus (SLE)

Okamoto H, Kaneko H, Terai C. Kamatani N.

Ann Rheum Dis. 2007; 66: 1263-1264.

What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity.

Iikuni N, Nakajima A, Inoue E, Tanaka E, Okamoto H, Hara M, Tomatsu T, Kamatani N, Yamanaka H.

Rheumatology (Oxford). 2007;46:846-8.

Disturbances of the symphysis pubis in rheumatoid arthritis: Report of two cases.

Tsukahara S., Momohara S., Ikari K., Murakoshi K., Mochizuki T., Kawamura K., Kobayashi S., Nishimoto K.,Okamoto H., Tomatsu T.

Modern Rheumatology 2007;17:344-7.

Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort.

Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, Kamatani N, Yamanaka H.

J Rheumatol. 2007 ;34:964-8.

Interleukin-12/23 monoclonal antibody for psoriasis.

Okamoto H, Momohara S.

N Engl J Med. 2007 ;356:2003.

Vancomycin-induced immune thrombocytopenia.

Okamoto H.

N Engl J Med. 2007 ;356:2537.

Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS(3)PE) Syndrome Accompanied by Parkinson's Disease.

Ito E, Okamoto H, Mochizuki A, Ohara K, Kato M, Terashima Y, Tanaka E, Takagi K, Uchiyama S, Iwata M.

Intern Med. 2007;46:1139-42.

Antibodies to bovine serum albumin do not affect the results of enzyme-linked immunosorbent assays for IgG anti-NR2 glutamate receptor antibodies: Reply to the letter by Hirohata et al.

Yoshio T, Okamoto H, Minota S.

Arthritis Rheum. 2007 ;56:2813-2814

Anti-arthritis effects of vitamin K(2) (menaquinone-4) - a new potential therapeutic strategy for rheumatoid arthritis.

Okamoto H, Shidara K, Hoshi D, Kamatani N.

FEBS J. 2007 ;274:4588-94.

Dermatan sulfate in the synovial fluid of patients with knee osteoarthritis.

Momohara S, Okada N, Ikari K, Mizuno S, Okamoto H.

Mod Rheumatol. 2007;17:301-5.

A role of monocyte chemoattractant protein-4 (MCP-4)/CCL13 from chondrocytes in rheumatoid arthritis.

Iwamoto T, Okamoto H, Kobayashi S, Ikari K, Toyama Y, Tomatsu T, Kamatani N. Momohara S.

FEBS J. 2007 ;274:4904-12.

A case of Castleman's disease associated with diffuse idiopathic skeletal hyperostosis and ossification of the posterior longitudinal ligament of the spine.

Kobayashi S, Momohara S, Ikari K, Mochizuki T, Kawamura K, Tsukahara S, Nishimoto　K, Okamoto H, Tomatsu T.

Mod Rheumatol. 2007;17:418-21.

Raised monocyte chemotactic protein 1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus (NPSLE)

Iikuni N., Okamoto H., Yoshio T., Sato E., Kamitsuji S., Iwamoto T., Momohara S., Taniguchi A., Yamanaka H., Minota S. ,Kamatani N.

Ann Rheum Dis. 2006 ;65:253-6.

Effect of rituximab in refractory SLE-Inhibition of Th1?

Okamoto H.

Rheumatology (Oxford). 2006 ;45:121-2.

A CCR-5 antagonist inhibits the development of adjuvant arthritis in rat.

Okamoto H., Kamatani N.

Rheumatology (Oxford). 2006 ;45:230-2.

Monocyte Chemoattractant Protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis.

Iwamoto T, Okamoto H, Iikuni N, Takeuchi M, Toyama Y, Tomatsu T, Kamatani N, Momohara N.

Rheumatology (Oxford). 2006 ;45:421-4.

Rapidly destructive knee arthropathy associated with hepatitis B.

Momohara S, Okamoto H, Tokita N, Tomatsu T, Kamatani N.

Clin Exp Rheumatol 2006 ;24:111-2.

IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients.

Okamoto H, Iikuni N, Kamitsuji S, Yoshio T, Minota S, Kamatani N.

Rheumatology (Oxford). 2006 ;45:232-4.

Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.

Hirata S, Okamoto H, Ohta S, Kobashigawa T, Uesato M, Kawaguchi Y, Tateishi M, Hara M, Kamatani N, Tsai HM.

Rheumatology (Oxford). 2006 ;45:1046-7.

A case of severe acute pancreatitis, in overlap syndrome of systemic sclerosis and systemic lupus erythematosus, successfully treated with plasmapheresis.

Suzuki Y, Okamoto H, Koizumi K, Tateishi M, Hara M, Kamatani N.

Mod Rheumatol. 2006;16:172-5.

Mouse monoclonal anti-human thrombomodulin antibodies bind to and activate endothelial cells through NF-kappaB activation in vitro.

Nara H, Okamoto H, Minota S, Yoshio T.

Arthritis Rheum. 2006 ;54:1629-37.

Corticosteroids in ARDS.

Okamoto H.

N Engl J Med. 2006 ;355:317;

Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus.

Sato E., Iikuni N, Yoshio T, Minota S, Kamatani N, Okamoto H.

Ann Rheum Dis 2006; 65: 1257-1259.

Successful treatment with fenofibrate of autoimmune hepatitis in a patient with rheumatoid arthritis.

Okamoto H, Kamatani N.

Scand J Rheumatol. 2007 ;36:235-6.

Stimulatory autoantibodies to the PDGF receptor in scleroderma.

Okamoto H.

N Engl J Med. 2006;355:1278-9.

Neglected spontaneous rupture of the Achilles tendon in patients with systemic lupus erythematosus associated with long-term steroid use.

Murakoshi K., Momohara S., Ikari K., IwamotoT., Kawamura K., Tomatsu T., Okamoto H.

Mod Rheumatol. 2006;16:324-6.

Tumor necrosis factor inhibitors for rheumatoid arthritis.

Okamoto H.

N Engl J Med. 2006 ;355:2046-2048.

Evaluation of pnemocysitis pneumonia infection risk factors in patients with connective tissue disease.

Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M.

Mod Rheumatol. 2006;16:282-8.

The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis.

Mochizuki T, Momohara S, Ikari K, Okamoto H, Kobayashi S, Tsukahara S, Iwamoto T, Kawamura K, Saitoh S, Tomatsu T.

Mod Rheumatol. 2007;17:24-7.

High CCL18/PARC Expression in Articular Cartilage and Synovial Tissue of Patients with Rheumatoid Arthritis.

Momohara S, Okamoto H, Iwamoto T, Mizumura T, Ikari K, Kawaguchi Y, Takeuchi M, Kamatani N, Tomatsu T.

J Rheumatol. 2007 ;34:266-71.

MHC2TA is associated with rheumatoid arthritis in Japanese patients.

Iikuni N, Ikari K, Momohara S, Tomatsu T, Hara M, Yamanaka H, Okamoto H, Kamatani N.

Ann Rheum Dis. 2006 66:274-5.

Chaperonin 10 for rheumatoid arthritis.

Okamoto H.

Lancet. 2006 ;368:1961-1961.

Single nucleotide polymorphisms in the gene encoding the MHC class II transactivator (CIITA) in Systemic Lupus Erythematosus (SLE).

Okamoto H., Iikuni N., Nakamura T., Kawamoto M., Momohara S., Ichikawa N., Furuya T., Kotake S., Taniguchi A., Yamanaka H.,Kamatani N.

Ann Rheum.Dis, 2005; 64: 947-950.

A role for TARC/CCL17, a CC chemokine, in New Zealand Mice.

Okamoto H., Nishimura H., Kamatani N.

Rheumatology, 2005; 44; 819-820.

Inhibition of NF-KB signaling by fenofibrate, a peroxisome proliferator activated receptor-α ligand, present a therapeutic strategy for rheumatoid arthritis.

Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., Kamatani N.

Clin Exp Rheumatol. 23: 323-30, 2005.

Plasma concentration of TARC/CCL17 is elevated in nonepisodic angioedema associated with eosinophilia.

Okamoto H., Kamatani N.

Allergy 60: 1091-2, 2005

An Angiotensin Receptor Blocker Suppresses MCP-1 Production From Rheumatoid Synovial Fibroblasts: comment on the article by Sagawa et al.

Iikuni N., Okamoto H., Kasahara M.,, Kamatani N.

Arthritis Rheum. 2005 ;52:4047-8.

The Study of Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Active Rheumatoid Arthritis.

Momohara S, Okamoto H, Yago T, Furuya T, Nanke T, Kotake S, Soejima M, Mizumura T, Ikari K, Tomatsu T.

Mod Rheumatol 2005. 15 : 410-14.

Myelodysplastic Syndrome Associated with Low Dose Methotrexate in Rheumatoid Arthritis.

Okamoto, H., Teramura, M. and Kamatani, N.

The Annals of Pharmacotherapy. 2004. 38: 172-173.

Ulcerative Colitis followed by the development of Beh?et's Disease.

Kobashigawa T, Okamoto H, Kato J, Shindo H, Imamura T, Iizuka BE, Tanaka M, Uesato M, Ohta SJ, Terai C, Hara M, Kamatani N.

Internal Medicine 2004. 43: 243-247.

Successful Treatment with Fenofibrate, a PPAR-alpha ligand, for a patient with Rheumatoid Arthritis.

Okamoto H., Kamatani N.

Ann Rheum.Dis, 2004. 63: 1002-1003.

Dermatomyositis Associated with Autoimmune Idiopathic Thrombocytopenia (AITP) and Anti-Ku Antibody.

Okamoto H., Soejima M., Takeuchi M., Tateishi M., Terai C., Hara M., Saito T., Kamatani N.

Mod Rheumatol. 2004. 14: 187-190.

Vasopressin cell antibodies and central diabetes insipidus in a patient with systemic lupus erythematosus and dermatomyositis.

Kajiyama H, Terai C, De Bellis A, Bizzarro A, Bellastella A, Ohta S, Okamoto H, Uesato M, Hara M, Kamatani N.

J Rheumatol. 2004. 31:1218-1221.

Endoscopic ultrasonograms in patients with Behcet’s colitis.

Okamoto H., Shindo H., Kamatani N.

Mod Rheumatol 2004. 14: 331-332.

IP-10/CXCL10 is increased in the cerebrospinal fluid of CNS lupus patients.

Okamoto H., Katsumata Y., Nishimura K., Kamatani N.

Arthritis Rheum. 2004. 50: 3731-2.

Myocardial dysfunction in a patient with adult-onset Still’s disease (AOSD).

Nishimagi E., Hirata S., Kawaguchi Y., Okamoto H., Hara M., Kamatani N.

Clin Exp Rheumatol 2004. 22: 506-7.

MMP-28/Epilysin expression in cartilage from rheumatoid arthritis and osteoarthritis: comment on the articles by Kevorkian L et al.

Momohara S, Okamoto H, Komiya K, Ikari K, Takeuchi M, Tomatsu T, Kamatani N.

Arthritis Rheum. 2004. 50: 4074-4075.

Rituximab for rheumatoid arthritis.

Okamoto H., Kamatani N.

N Engl J Med. 2004. 351: 1909.

Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.

Okamoto H., Terai C., Kamatani N.

BJU Int. 2004. 94:1401-2.

A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus.

Okamoto, H,, Koizumi, K., Yamanaka, H., Saito, T.,and Kamatani, N.

J. Rheumatol, 2003. 30:2369-73,

RelA-associated Inhibitor (RAI) Blocks Transcription of Human Immunodeficiency Virus Type 1 by Inhibiting NF-kB and Sp1 Actions.

Takada, N., Sanda, T., Okamoto, H., Yang, J-P., Asamitsu, K., Sarol, L., Kimura, G., Uranishi, H., Tetsuka, T., and Okamoto T.

J. Virol. 2002. 76; 8019-8030.

Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines.

Mori T., Okamoto H., Takahashi N., Ueda R. Okamoto T.

FEBS Letters 2000. 465, 124-128.

HIV-1 replication is inhibited by a pseudo- substrate peptide that blocks Tat transactivation.

Okamoto H., Cujec,T. P., Peterlin, B. M., Okamoto, T.

Virology 2000. 270, 337-344.

Inhibition of the RNA-dependent transactivation and Replication of HIV 1 by A Fluoroquinoline Derivative K-37.

Okamoto H., Cujec,T. P., Okamoto M., Baba M., Peterlin, B. M., Okamoto, T.

Virology 2000. 272, 402-408.

Reciprocal modulations of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA.

Okamoto H., Asamitsu, K., Nishimura, H., Kamatani, N. and Okamoto, T.

Biochem Biophys Res Commun. 2000. 279, 494-499.

Mechanisms by which the HIV-encoded Tat protein increases the efficiency of transciptional elongation by RNA polymerase II.

Okamoto H., , Peterlin, B. M. and Cujec,T. P.

Acta Biologica slovenica 2000. 43, 99-108.

Anti-rheumatic compound aurothioglucose inhibits TNF-a induced HIV-1 replication in latently infected OM10.1 and Ach2 cells.

Traber, K.E., Okamoto, H., Kurono, C., Baba, M., Saliou, C., Soji, T., Packer, L. and Okamoto, T.

Int. Immunol. 1999. 11, 143-150.

Sequence-independent inhibition of RNA transcription of DNA dumbbells and other decoys.

Lim, C. S., Jabrane-Ferrat, N., Fontes, J. D., Okamoto, H., Garovoy, M. R., Peterlin, B. M., and Hunt, C. A.

1997. Nucleic. Acid Research 25, 575-581.

The HIV trans-activator Tat binds to the CDK-activating kinase (CAK) and activates the phosphorylation of the c-terminal domain of RNA polymerase II.

Cujec., T. P., Okamoto, H., Fujinaga, K., Meyer, J., Chamberlin, H., Morgan, D. O., and Peterlin, B. M.

Genes & Dev. 1997. 11, 2645- 2657.

Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II.

Okamoto, H., Sheline, C. T., Corden, J. L., Jones, K. A., and Peterlin, B. M.

Proc. Natl. Aca. Sci. USA 1996. 93, 11575-11579.

Functional CD4+ T cell subsets defined by expression of CD45RC and NTA260 antigens and age-associated polarization in murine lupus.

Nishimura, H., Hattori, S., Ueda, G., Abe, M., Yang, K., Nozawa, S., Okamoto H., Zhang, D., Tsurui, H., Hirose, S., and Shirai, T.

Int. Immunol. 1995. 7: 1115-1123.

Molecular cloning revealed a unique murine B cell differentiation antigen Lp-3 as an epitope of leukosialin (CD43).

Shiota, J., Nishimura, H., Okamoto, H., Hattori, S., Abe, M., Okada, T., Nozawa, S., Hirose, S., Shirai, T.

Cell. Immunol.,1994. 155: 402-413.

Pulmonary hypertension in systemic lupus erythematosus- a report of an autopsied case.

Sato, M., Okazaki, H., Okamoto, H., Ohtaka, A., Minato, N., Shimizu,T., Kano, S.

Internal Medicine 1994. 33:540-542.

H-2z Homozygous New Zealand mice as a model for B-cell chronic lymphocytic leukemia: Elevated bcl-2 expression in CD5 B cells at premalignant and at malignant stages.

Okamoto, H., Nishimura, H., Shinozaki, A., Hirose, S., Shirai, T.

Jpn. J. Cancer Res. 1993. 84: 1273-1278.

Differential expression of three CD45 alternative structures on murine T cells: Exon 6-dependent epitope as a marker for functional heterogeneity of CD4+ T cells.

Nishimura, H., Hattori, S., Abe, M., Ueda, G., Okamoto H., Tsurui, H., Hirose, S., Shirai, T.

Int. Immunol. 1992. 4: 923-930.

Ebz of NZW mice is identical with Ebu of B10.PL mice.

Nishimura, H., Okamoto, H., Ogawa, S., Hirose, S., and Shirai, T.

Immunogenetics 1991. 33: 413-414.

Regulation of Na+,K +- ATPases II. Cloning and analysis of the 5'-flanking region of the rat NKAB2 gene encoding the β2 subunit .

Kawakami, K., Okamoto, H., Yagawa , Y.,and Nagano, K.

Gene 1991. 91: 271-274.